Introduction
Transcatheter aortic valve replacement (TAVR) was first performed in 2002 and is increasingly used to treat patients with aortic stenosis, including patients at intermediate surgical risk. [1] [2] [3] Until recently, most patients have been treated with the balloon-expandable (Edwards SAPIEN) or the self-expandable (Medtronic CoreValve) transcatheter heart valve (THV). 4 These valves have gone through a series of developments, but the fundamental characteristics of both valves remained relatively unchanged except for the addition of a sealing skirt to the SAPIEN valve and possibility of recapturing of the CoreValve Evolut valve. Paravalvular aortic regurgitation (PAR) has been an important limitation of early generation THVs designs because of its association with increased late mortality. [5] [6] [7] This may in particular be a concern when TAVR is offered to intermediate and low-risk patients because the left ventricle may be exposed to a certain degree of volume overload over a longer period. The addition of a collar at the inflow of the Edwards SAPIEN3 (SAPIEN3) is associated with a significant reduction in PAR. 4, 8, 9 This also applies to the more recently introduced mechanically expanding Lotus THV. 10 Head-to-head comparison of haemodynamic performance and the incidence of PAR after TAVR between the SAPIEN3 and the Lotus THVs in an independent core laboratory setting is not available, as no randomized studies have been performed yet. In this study, we sought to compare the valve performance and PAR after Lotus and SAPIEN3 implantation using pre-discharge transthoracic echocardiography (TTE) and independent core laboratory analysis.
Methods

Study population
This is a single-center, observational study encompassing 162 consecutive patients who underwent TAVR because of severe aortic stenosis with either the Lotus (n ¼ 79) or the SAPIEN3 (n ¼ 83) THVs between September 2013 and December 2015. Eligibility for TAVR and vascular access (i.e. femoral, axillary and apex) was decided during the multidisciplinary valve team discussion. Exclusion criteria included valve-in-valve procedure or TAVR because of aortic regurgitation (AR) and patients without echocardiographic follow-up. Flow chart of the study population is shown in Figure 1 . Patients were first seen at the outpatient clinic and gave written informed consent for anonymized prospective data collection for clinical research purpose per local ethics committee approved (TAVI Care and Cure project, MEC-2014-277).
Pre-procedural assessment and treatment
All patients underwent pre-procedural multi-slice computed tomography (MSCT) of the aortic valve and peripheral vasculature before TAVR. Technical details of MSCT acquisition were described previously.
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MSCT scans were analysed by an expert reader using the 3Mensio valve analysis program (3Mensio Medical Imaging, Bilthoven, The Netherlands. 12 For the purpose of the study, the following derived parameters were calculated in addition to the standard set of direct quantitative aortic root measures namely: aortic annulus (minimum, maximum diameters, perimeter and area) and perimeter-and area-derived diameters. In addition, left ventricular outflow tract (LVOT) area-derived diameter was also measured. Sizing index defined by nominal THV diameter or area/aortic annulus or LVOT diameter or area), Cover Index was defined by 100 Â (nominal THV diameter À CT diameter)/nominal THV diameter and the Eccentricity Index defined by 100 Â [1 À (aortic annulus minimum diameter/maximum diameter)].
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TAVR treatment
The Lotus and SAPIEN3 valves were the devices of first choice in our centre. All TAVR procedures were performed according to standard practice. The choice of the valve type was at the operator's discretion. Valve size was based upon MSCT and the manufacturer's guidelines for sizing.
Assessment of valve performance
TTE was performed before hospital discharge using the 'iE33, the EPIQ 7C ultrasound system' (Philips Medical System, Best, the Netherlands) and the 'ACUSSON SC2000' (Siemens, Germany) conform a predefined acquisition protocol. Pulsed-and continuous-wave Doppler signals were recorded at a sweep speed of 50-100 mm/s. Colour Doppler recordings were optimized for display with the colour velocity scale at 660 (50-70 cm/s) during the entire study. All TTEs were analysed by experienced analysts in accordance with published guidelines using the Image Arena Platform (TomTec Imaging Systems, Unterschleissheim, Germany) who were blinded to patient-and procedure related variables except for patient's height and weight. [13] [14] [15] Analyses were approved by one experienced echocardiologist (O.S.). The presence, location and severity of AR (central, paravalvular and total) were adjudicated according to the core laboratory standards in line with American and European guidelines. [15] [16] [17] [18] [19] Corelab standards included determination of AR according to the paravalvular aortic regurgitation severity (PARS) model ( Figure 2 ). The latter represents the assessment of the presence, location and severity of AR on colour Doppler images at 18 locations in four TTE views. PAR locations were assigned to one or more of the 12 locations based on a face of a clock model on the cross-sectional parasternal short-axis view. PAR location was assigned as either anterior or posterior on the parasternal long-axis, apical five-chamber and apical threechamber views. For severity, PAR jet(s) were quantified in the Parasternal short-axis (PSAX) as colour areas, radial width (equivalent to jet neck width) and the SAX circumferential extent in degrees. Only areas of mosaic colour reflecting turbulent flow high-velocity PAR jet(s) were measured. PAR jets were then measured when appropriate for radial width (perpendicular to the flow and LVOT). Based on the above locations, three quantitative scores were calculated namely: 'the PARS radial score' (similar to vena contracta width) defined as sum of maximum radial width of PAR jet(s) measured in all 18 locations; 'the PARS area score' (similar to vena contracta areas) defined as the sum of all PAR areas in the 12 locations on parasternal short-axis view; and the 'PARS-SAX score' is calculated as the sum degrees of circumferential occupancy of PAR jet(s) in the 12 locations on the parasternal SAX view divided by 360.
AR volume was calculated as LVOT stroke volume-right ventricular outflow tract stroke volume and divided by the LVOT stroke volume to provide AR fraction. Diastolic flow reversal in the descending thoracic or abdominal aorta was also determined. Using a combination of all available parameters, patients were allocated into one-of six-class grading scheme (none/trace, mild, mild-to-moderate, moderate, moderate-to-severe and severe). 22 We used the cut-off points defined by guidelines 19 and Valve Academic Research Consortium 2 (VARC-2) criteria 16, 17 and experts' consensus. 22 The six-class grading scheme was then collapsed into a four-class grading scheme of none-trace, mild, moderate and severe. Mild and mild-to-moderate classes were taken together, as well as moderate and moderate-to-severe. 23 
Study endpoint
The primary endpoint of the study was valve performance as intended by TTE at discharge or 30-day whichever came first, in accordance with VARC-2 16, 17 . Because second-generation devices are designed to eliminate PAR, we used modified definition for VARC-2 to include mild AR in the composite endpoint. Because PPM is debatable, we used another VARC-2 modification to define haemodynamic success that disregard PPM as a requirement of device success. Thus, devices are compared in relation to four VARC-2 definitions: original: no stenosis, no PPM and no moderate or severe AR; modification 1: no stenosis, no PPM and no AR (mild, moderate or severe); modification 2: no stenosis, no moderate or severe AR and modification 3: no stenosis, no AR (mild, moderate or severe).
Statistical analysis
Continuous variables are summarized as mean 6 SD or median (interquartile range) and categorical variables as absolute frequencies and percentages. Normality of distributions for continuous variables was tested using the Shapiro-Wilk test. Statistical significance between continuous variables was tested using the appropriate t test or nonparametric test (the Wilcoxon test for paired samples and the MannWhitney U test for independent samples). Categorical variables were compared using v 2 or Fisher's exact tests. Univariate and multivariate analyses were used to test the association between mild or more AR and demographic, anatomic and procedural variables. Statistical analysis was performed with SPSS 23 (IBM, Armonk, NY, USA). All probability values were two tailed, and value of P < 0.05 was considered significant.
Results
The baseline clinical and procedural characteristics of the study population are shown in Tables 1 and 2 . Except for a slightly larger aortic annulus area, perimeter, perimeter-derived diameter and LVOT (perimeter and area) in patients treated with the SAPIEN3 THV; there was no difference in the baseline characteristics between the Lotus and SAPIEN3 patients. The transfemoral approach was used in all Lotus-and in 75 (90%) SAPIEN3-treated patients. The use of balloon pre-dilatation was similar [12 (15%) vs. 18 (22%), P ¼ 0.20] in the Lotus-and SAPIEN3-treated patients, respectively. Yet, the balloon size was larger in the SAPIEN3 group (19.5 6 2.0 vs. 23.7 6 2.0 mm; P < 0.001). The SAPIEN3 cohort had overall larger sizing and cover indices ( Table 2) , albeit small but statistically significant (P <0.01). Post-TAVR balloon dilatation was performed in 11 (13%) of the SAPIEN3-treated patients.
Valve performance
The primary endpoint (VARC-2 intended valve performance, no stenosis, no moderate or severe AR, and no PPM) was reached in 71% and 76% in the Lotus-and SAPIEN3-treated patients, respectively Figure 2 The standard four views, which are used to assess AR severity in the PARS model: the parasternal short-axis view (left) superimposed a face of a clock for simple estimation of PAR location, the apical five-chamber view (second left), the apical three-chamber view (second right), and the parasternal long-axis view (right). Numbers from 1 to 18 refer to a location in relation to the native aortic cusps and anatomic orientation (for details, see text), the parasternal short-axis. 5CH, the apical five-chamber view; 3CH, the apical three-chamber view; C (or IST), commissure (or intersinus triangle), LCC, left coronary cusp; NCC, non-coronary cusp; PLAX, parasternal long-axis view; RCC, right coronary cusp. (P ¼ 0.59). Modified VARC-2 intended valve performance, no stenosis, no moderate or more AR was reached in 99% and 96% in the Lotus-and SAPIEN3-treated patients, respectively (P ¼ 0.98). The distribution of failure to meet the components of the VARC-2 criteria is summarized in Table 3 . Detailed TTE-derived haemodynamic parameters are summarized in Table 4 . Supplementary data online, Table S1 , lists the haemodynamic performance per THV size.
AR
Location of PAR Overall, PAR was less often seen in the SAX compared with the three long-axis views with a similar frequency of PAR in the apical five-chamber ($15%) and the apical three-chamber ($15%) views (Figure 3) . In the parasternal short-axis view, the 2 o'clock location (i.e. corresponding with location of the right aortic cusp) showed more often PAR jets ($5%) compared with the 6 o'clock to 10 o'clock locations (i.e. corresponding with location of the left and non-coronary aortic cusp and aortic-mitral curtain) (Figure 4) . Numerically more PAR jets were seen in the SAPIEN3-treated patients at all 18 locations of the PARS model except at 11 and 12 o'clock (3% and 4% vs. 2% and 2%, in the Lotusand SAPIEN3-treated patients, respectively). None of the Lotustreated patients had PAR in the 6 o'clock to 10 'clock territory. (Table 5) . Overall, there has been no significant interaction between the MSCT-based sizing indices nor cover indices and incidence of mild or more AR. Moreover, the latter was confirmed visually ( Figure 5) . On univariate analysis, the use of balloon post-dilatation (odds ratio, OR ¼ 3.98, P ¼ 0.03), and the use of 
Severity of AR
Discussion
This single-centre, observational study evaluated valve performance by independent core laboratory analysis in 162 patients treated with the Lotus or SAPIEN3 valve. The main finding is that the Lotus valve was associated with less AR than SAPIEN3 despite a lower cover index in patients treated with a Lotus valve. Outcome of TAVR depends on-among others-valve performance that has substantially been improved by, for instance, the addition of a paraprosthetic cuff to reduce AR. 24, 25 In this study, the frequency of mild or more AR was 15% after Lotus valve implantation. It was 35% after SAPIEN3 valve implantation. The question is whether this observation is a finding by chance because of the observational nature of the study with its intrinsic limitations because of bias in patient selection and/or observation in addition to eventual differences in operator performance such as differences in the depth of implantation that was not measured or whether it is a true phenomenon because of differences in the valve design. The presence of a true difference is supported by the findings of the multivariate analysis in which the SAPIEN3 valve had an increased risk of PAR when compared with the Lotus valve. There is also evidence from previous research that valves do differ in terms of valve performance, AR in particular. The CHOICE study compared the SAPIEN XT and CoreValve by means of a randomized clinical trial and showed significantly less AR after SAPIEN valve implantation (mild or more AR: 34% vs. 51%). It should be acknowledged that at variance with this study, echo assessment in the CHOICE study consisted of on site evaluation by an experienced interventional echocardiographer. 26 A recent non-randomized core laboratory evaluation (VARC-2) of the Lotus and CoreValve reported a frequency of mild or more PAR of 18% after Lotus valve implantation and 72% after CoreValve. 27 Of note, the frequency of PAR after
Lotus and SAPIEN3 valve implantation in this study is similar to an observational study with the Lotus valve, 25,27 on one hand, and with the recent publication of TAVR with the SAPIEN3 valve in patients at intermediate risk (mild and more: 35% vs. 40%, moderate: 3.6% vs. 1.5%, respectively). 28 The question remains how this difference in PAR in favour of the Lotus valve over the SAPIEN3 is to be explained. Frame geometry analysis post TAVI has revealed that both the Lotus and SAPIEN valve virtually reach complete expansion and a circular configuration. 29, 30 This may indicate a better sealing effect of the cuff of the Lotus valve in combination with a denser configuration of the frame of the Lotus valve.
The clinical relevance of efforts to eliminate PAR is indicated by the findings that even mild PAR is associated with impaired prognosis. [5] [6] [7] This may, in particular, become important when TAVR moves to the low-risk patient, as the ventricle will be exposed to a longer lasting period of volume overload albeit small. Yet, this is the subject have not only protective effects (e.g. prevention of sudden cardiac death) but also adverse effects on cardiac performance because of, for instance, interventricular dyssynchrony. There, thus, is a pacemaker-PAR trade-off or dilemma and as TAVR moves to the low-risk patient, one needs to assess what harms the patient the most. The optimal technique to assess and define PAR is the subject of debate. Conceptually, Magnetic Resonance Imaging (MRI) is superior in terms of precision and accuracy in grading PAR but is in clinical practice often not feasible because of logistic issues or contraindications to perform MRI. 31, 32 In this study, not only a comprehensive echo core laboratory algorithm was used to assess the location and severity of PAR and included the VARC-2 Doppler and 2D echocardiographic parameters of AR assessment but also three novel core laboratory developed PARS scores that we believe is necessary for proper PAR assessment. In particular, the PARS radial score proved to be important when AR was not seen in the parasternal SAX view. This is explained by the often eccentric nature of PAR that is difficult to image in the axial plane (short-axis view) where one can appropriately quantify PARS SAX and PARS areas scores. Of note, Doppler signals indicating PAR were seen in all patients with AR in any of the three PARS long-axis views of the heart. Therefore, the three long-axis views are of real help to improve diagnosis of PAR. We did not provide, however, cut-off values for the PARS area or PARS radial scores but used the ones proposed by Hahn et al. 23 PARS cut-off values need validation against ref-
erence method or outcome data. In addition, we used the six-class grading scheme that was shown to improve the reproducibility of PAR grading when collapsed to the VARC-2 four-class grading scheme. We reported the study findings according to the collapsed four-class scheme (none or trace, mild, moderate or severe) that is familiar to clinicians.
Clinical perspectives
TAVR using early generation THVs is widely recognized as an effective treatment in intermediate, high-risk and inoperable patients with severe aortic valve stenosis. The excellent results of the first-generation THVs are limited by excess incidence of paravalvular AR. The latter is particularly important with the intent of the expansion of TAVR indications toward lower-risk patients Antileakage sealing mechanisms are added to the newly designed second-generation devices. Impact of MSCT sizing algorithms in the second-generation THVs is not known. Head-to-head comparison of the Lotus and SAPIEN3 second-generation THVs in a controlled core laboratory setting has not previously performed. This prospective study showed that TAVR using the Lotus and SAPIEN3 second-generation THVs is effective in reducing moderate or more AR. Mild or more AR is more frequent in the SAPIEN3 despite more often use of balloon post dilation. The Lotus and SAPIEN3 THVs have a comparable haemodynamic profile at 30-day after TAVR. MSCT-based oversizing and cover index are not related to 
Limitations
The present findings stem from a single-centre study with a relatively small sample size. Yet, all echocardiographic analyses were performed by an independent core laboratory.
Conclusions
Overall, haemodynamic performance was comparable between the Lotus and SAPIEN3 valves. Despite a smaller cover index, there was less AR of any grade after Lotus compared with SAPIEN3 valve implantation.
Supplementary data
Supplementary data are available at European Heart Journal -Cardiovascular Imaging online.
